BC
GTHX

Boxer Capital’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Boxer Capital’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-660,000
Closed -$24.5M – 31
2018
Q1 		$24.5M Buy
660,000
+30,821
+5% +$822K 2.61% 14
2017
Q4 		$12.5M Hold
629,179
– – 2.28% 13
2017
Q3 		$15.7M Hold
629,179
– – 3.57% 9
2017
Q2 		$11M Buy
+629,179
New +$11M 2.61% 11

Other funds holding GTHX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Boxer Capital's GTHX Position: Q2 2018 in Review

Boxer Capital sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q2 2018, closing a stake of 660,000 shares — an estimated $24.5M sold.

Boxer Capital first reported a position in GTHX in Q2 2017 and held it in 4 quarters. The position peaked at $24.5M in Q1 2018. 95 funds tracked by Wall St. Rank hold GTHX as of Q2 2018.

  • Boxer Capital reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • Boxer Capital sold 660,000 G1 Therapeutics, Inc. Common Stock shares in Q2 2018, an estimated $24.5M.
  • Boxer Capital first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2017 and held it in 4 quarters.
  • Boxer Capital's G1 Therapeutics, Inc. Common Stock position peaked at $24.5M in Q1 2018.
  • 95 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q2 2018.

Based on Boxer Capital's 13F filing for Q2 2018, filed 14 Aug 2018.